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Abstract
Background: The presence of various levels of Adenovirus serotype 5 neutralizing antibodies (Ad5NAb) is thought to
contribute to the inconsistent clinical results obtained from vaccination and gene therapy studies. Currently, two platforms
based on high-throughput technology are available for Ad5NAb quantification, chemiluminescence- and fluorescence-
based assays. The aim of this study was to compare the results of two assays in the seroepidemiology of Ad5NAb in a local
population of donors.
Methodology/Principal Findings: The fluorescence-based neutralizing antibody detection test (FRNT) using recombinant
Ad5-EGFP virus and the chemiluminescence-based neutralizing antibody test (CLNT) using Ad5-Fluc were developed and
standardized for detecting the presence of Ad5NAb in serum samples from the population of donors in Beijing and Anhui
provinces, China. First, the overall percentage of people positive for Ad5NAb performed by CLNT was higher than that
obtained by FRNT (85.4 vs 69.9%, p,0.001). There was an 84.5% concordance between the two assays for the 206 samples
tested (144 positive in both assays and 30 negative in both assays). All 32 discordant sera were CLNT-positive/FRNT-negative
and were confirmed positive by western blot. Secondly, for all 144 sera positive by both assays, the two assays showed high
correlation (r=0.94, p,0.001) and close agreement (mean difference: 0.395 log10, 95% CI: 20.054 log10 to 0.845 log10).
Finally, it was found by both assays that there was no significant difference observed for titer or prevalence by gender
(p=0.503 vs 0.818, for two assays); however, age range (p=0.049 vs 0.010) and geographic origin (p=0.007 vs 0.011) were
correlated with Ad5NAb prevalence in northern regions of China.
Conclusion: The CLNT assay was relatively more simple and had higher sensitivity than the FRNT assay for determining
Ad5NAb titers. It is strongly suggested that the CLNT assay be used for future epidemiological studies of Ad5NAb in other
localities.
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Introduction
Adenoviruses include a large family of non-enveloped, double-
stranded DNA viruses, which generally cause respiratory diseases
and ocular diseases in humans of all age groups in addition to
gastrointestinal disorders in children [1]. Adenovirus serotype 5
(Ad5) is widely used as a vehicle for vaccine delivery for the
treatment of infectious disease and cancer [2–4]. However, the
efficacy of Ad5 vectors has been limited in humans because
exposure to natural Ad5 infections results in a high percentage of
potential vaccinees having neutralizing antibodies against Ad5
(Ad5NAb), particularly in the developing world [5–9]. Therefore,
it is necessary to determine the prevalence of Ad5NAb in a study
population before the administration of Ad5 vector-based products
[10,11].
Ad5NAb titer is typically obtained by transgene expression
inhibition and replication inhibition with plaque scoring [12].
Quantitative analysis based on the transgene expression inhibition
is supported by previous data that showed the number of
recombinant virus particles bound to cells was directly propor-
tional to transgene expression [13]. A series of enzyme-activated
chemiluminescence-based neutralizing antibody detection test
(CLNT) have been developed for the detection of Ad5NAb,
including firefly luciferase (Fluc), b-galactosidase, and secreted
alkaline phosphatase reporter genes [14–17]. Enhanced green
fluorescent protein (EGFP) has also been widely used as a reporter
gene in transgene expression inhibition assays, known as the
fluorescence-based NAb detection test (FRNT) [18,19]. Currently,
most available Ad5NAb assays have employed CLNT and FRNT
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dynamic range, simplicity, and significant increase in laboratory
throughput.
Several studies have been conducted with CLNT and FRNT for
their efficacies of detecting Ad5NAb. Rajendra et al [19] found
100% of sera from 114 representatives of an Indian adult
population had different titers of Ad5NAb using FRNT assay,
starting dilution at 1:10. However, Caijun et al [15] investigated
the epidemiology of Ad5NAb in healthy people in Guangzhou,
southern China using a CLNT assay and found a lower
seroprevalence (77.34%), starting dilution at 1:18. These studies
highlight that it is unknown how these two assays compare for
measuring Ad5NAb levels in human sera. Therefore, differences
in data obtained by these assays prove difficult to interpret and
compare since the sensitivity of the assays or prior exposure to Ad5
infection likely influences each assay differently. In the present
study, we describe a head-to-head comparison of the CLNT and
FRNT assays using sera from healthy individuals in Beijing and
Anhui provinces in northern China.
Results
Construction of Ad5-Fluc and Ad5-EGFP
After 4–5 rounds of propagation in HEK293 cells, insertion of
the Fluc and EGFP genes into the Ad5 genome, creating Ad5-Fluc
and Ad5-EGFP, respectively, and were confirmed by polymerase
chain reaction (PCR) and nucleotide sequencing. The amplified
Fluc and EGFP products have 100% nucleotide identity to
published sequences (GenBank Accession: EU921841 for Fluc,
DQ768212 for EGFP). As shown in Figure 1A and 1B, the
expression of luciferase and EGFP reporter genes were detected
using the CLNT and FLNT assays. The Ad5-Fluc (lot number:
20101225) and Ad5-EGFP virus stocks (lot number: 20101227)
were purified by cesium chloride gradient centrifugation, diluted
in phosphate-buffered saline (PBS) to a final concentration of
1610
12 virus particles (VP)/mL, titrated using ultraviolet spectro-
photometry, and stored at 280uC.
Optimization of conditions for the neutralization assay
Vero cells were infected with different doses of Ad5-Fluc or
Ad5-EGFP virus to determine the optimal concentration to be
used in the neutralization assay. Figure 1A shows the direct
correlation between Ad5-Fluc virus concentration of 31–8000 VP/
cell and reporter transgene expression (r
2=0.9998). However,
Ad5-EGFP virus at 31–1000 VP/cell was shown to be better
correlated with the percent of infected cells compared to 31–8000
VP/cell (r
2, 0.9959 vs 0.9613) (Figure 1B). Therefore, the upper
saturation limits of Ad5-Fluc and Ad5-EGFP were 8000 VP/cell
and 1000 VP/cell, respectively. Each data point in Fig. 1A and B
represented the average of three independent experiments, and the
standard deviations for all points were lower than 0.98%.
The neutralizing activity of an Ad5-vaccinated mouse serum
was compared using different virus concentration, 63,250, and
1000 VP/cell (Figure 1C–H). Approximately 40–60% virus
neutralization was observed at VP/cell ratios of 63,250 and
1000 with naı ¨ve mouse serum during the serum dilution ,30, but
declined to ,20% when the serum dilution was more than 30-fold
(data not shown). A 250 VP/cell ratio (middle of the linear range)
was chosen as the optimal virus infectious dose to perform the
assay for a lower coefficient of variation compared to 63 VP/cell
(p,0.05) (Figure 1D, E, G, H) and no significant difference
between the Ad5NAb titers of two assays (15886335 vs 1381664,
p=0.32) (Figure 1I and J). Moreover, comparison of the addition
of 5,000 cells/well and 30,000 cells/well in a 96-well plate showed
that the higher cell density had better reproducibility at 250VP/
cell, (CV, 7.1 vs 3.2% for CLNT and 5.2 vs 2.4% for FRNT)
(Figure 1D and G). The final formats of the Ad5NAb assays for
testing human sera are described in Table 1.
Measurement of human Ad5NAb using CLNT and FRNT
At the positivity threshold of $30, the overall percentage of
people with detectable Ad5NAb performed by CLNT was higher
than for FRNT (85.4 vs 69.9%, p,0.001). Median Ad5NAb titers
were .2-fold higher for the CLNT compared with the FRNT,
and the average Ad5NAb (log10) titer in the 206 human samples
measured by CLNT and FRNT assays were 2.8360.84 and
2.4560.84, respectively (p,0.001) (Table 2). As shown in Table 2,
the percentage of serum samples positive for Ad5NAb significantly
increased with age, from 54.2% to 77.8% with FRNT (p=0.049)
and from 70.8% to 92.6% with CLNT (p=0.010). However, there
was no significant difference in titer or prevalence by gender,
67.7% vs 72.0% (p=0.503) and 84.8% vs 86.0% (p=0.818),
respectively. It was determined that the sera collected from Anhui
Blood Center (BC) had a higher proportion of patients with
Ad5NAb than Beijing BC, 78.3% vs 61.0% with FRNT
(p=0.007) and 91.5% vs 79.0% with CLNT (p=0.011).
Comparison of CLNT and FRNT
Overall, there was 84.5% concordance between the two assays
for the 206 samples tested; 144 positive by both assays and 30
negative by both assays. The FRNT could not detect Ad5NAb
titers for 32 samples that were determined to be positive by the
CLNT assay, with a range of titers of 30–300. For the 144
concordant positive samples, CLNT showed excellent correlation
with FRNT (r=0.94, p,0.001) (Fig. 2A). Using regression
analysis, it was determined that Ad5NAbCLNT=0.782*(Ad5NAb
FRNT)+1.022. Bland-Altman analysis revealed a close agreement
(95.8%, 138/144) between the two assays: the results of the CLNT
were on average 0.395 log10 higher than determined by the FRNT
assay (Fig. 2B). Overall, the range for the mean difference between
the quantitative values measured by the two assays (62 standard
deviations) was 20.054 to 0.845 log10. Quantitative differences
outside the limits of agreement were only observed between
CLNT and FRNT assays for six samples.
Confirmation of NAb test with Western blot analyses
For confirmation of the CLNT and FRNT results by western
blot, 9 out of 32 CLNT-positive/FRNT-negative sera were
randomly selected for analysis. The results obtained by neutral-
izing antibody and western blot methods were consistent. As
shown in Fig. 3, the serum sample S79 with the highest Ad5NAb
titer had the strongest antigen recognition by western blot,
whereas the five CLNT-positive/FRNT-negative sera were
confirmed positive by western blot but with weak Ad5 specific
antigen recognition, with comparison to the uninfected HEK293
cells [20,21]. Seronegative samples determined by both assays
remained negative by western blot.
Discussion
Recombinant Ad5-based gene transfer vector platforms are
heavily utilized for both gene therapy and vaccine applications due
to their well understood biology that includes excellent safety, high
vector yields, and high transgene expression in a wide range of
eukaryotic cells [22–24]. Their usefulness for permanent gene
replacement is limited by their high immunogenicity, which results
in the rapid elimination of transduced cells through induction of T
and B cells to adenovirus antigens and the transgene product
Antibody Detection Assays for Ad5
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37532Figure 1. Optimization of conditions for CLNT and FRNT assays. (A) Dose-response between Ad5-Fluc virus inoculum and luciferase
transgene expression. (B) Dose-response between Ad5-EGFP virus inoculum and percent of infected cells. The x-axis indicated virus concentration,
ranging from 31–8000 VP/cell, added to 30,000 cells/well in a 96-well plate. Each data point represented the average of three experiments. (C–H)
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investigate the baseline Ad5NAb serostatus for guiding the
administration of Ad5 vector-based products.
To our knowledge, this is the first head-to-head comparison of
the two high-throughput platforms, CLNT and FRNT, currently
used in many studies. In this report we compared Ad5
neutralization assays to define an optimal assay based on the
criteria of simplicity, speed, and sensitivity. The principle of two
assays is the same: serum, transgenic reporter virus, and cells are
incubated, which allows antibodies present in the serum to
neutralize the virus, thereby inhibiting infection. Subsequently,
inhibition of virus infection can be detected by transgene
expression. To make the different assays easy to be compared,
we had composed one protocol for the two assays that, in our view,
represented the replication inhibition method commonly used.
Critical parameters, virus inoculation dose, and cell density, were
standardized to achieve reliable comparison of data from the two
methods using Fluc and EGFP transgene reporters, respectively.
The determination of optimal viral concentration is important
because the infectious dose must be lower in order to increase
assay sensitivity. However, the infectious dose must be high
enough to produce a signal that will allow measurement of
reduction due to neutralization.
In this assay, we determined that 250 VP/cell, which was
determined to be in the middle of the linear range of detection,
was appropriate for reproducibility and sensitivity. Similarly,
Sprangers et al [14] selected a dose of 500 VP/cell for Ad5NAb
experiments. The linear correlation obtained between the Ad5
vector concentration and Fluc transgene expression or percent of
infected cells supports the hypothesis of one virion-one transduc-
tion event [26]. It was found that both human and mouse sera had
nonspecific neutralization effects at 1:30 dilution. We believe that
this inhibition was mainly due to the decrease of Vero cell activity
affected by various species of serum. In this assay, the samples
were considered positive only when the inhibition percentage
reached 50%. In fact, all naı ¨ve samples at the starting dilution
(1:30) were determined to be negative although their inhibition
percentage ranged from 5–15%. Thus, an inhibition percentage
,50% would not affect the results of detection. It was found that
the nonspecific inhibition effect decreased as serum dilution
increased from 30 folds. Furthermore, with comparison to the
inhibition effect of specific Ad5NAbs, the nonspecific neutraliza-
tion effect could be ignored when the serum dilution was greater
than 30-fold.
The current study showed that the intermediate prevalence
(69.9 and 85.4%, respectively for the two assays) determined in
human sera obtained from the northern Chinese region was in
agreement with that reported for the southern Chinese region
using the CLNT assay and an Ad5 expressing a secreted alkaline
phosphatase (77.3%) [15]. Moreover, these data were also
consistent with those found for Ad5NAb seroprevalence in regions
of the world with lower seroprevalence, such as Europe and the
USA (35–70%) [9,18], and regions with a higher prevalence, such
as Africa and other Asian regions (75–100%) using CLNT or
FRNT assay [12,19]. As more Ad5 vector-based vaccines are
evaluated in diverse populations around the world, geographic
variation may be important in the design of future vaccine trials.
Interestingly, we found that the percentage of positive Ad5NAb
samples and serum titers significantly increased with age, with 18-
to 20-year-old individuals having the lowest levels of Ad5
immunity, which was consistent with the finding mentioned by
Caijun Sun, indicating that the older population (41–72 years) in
southern China had the highest seropositivity (84.8%) and
percentage (54.4%) of the high Ad5 neutralizing antibody titers
(.1000) [15]. This finding is likely to broaden the use of
recombinant Ad5-based vaccines to this age group of ,20 years.
We believed that the increase was due to the change in the social
behavior of individuals at this age, as when they move outdoors
and have increased contact with others, thus having a higher
chance of exposure to adenovirus.
The current study also determined that there was significant
variation in the prevalence of Ad5NAb between the populations of
donors from different geographic regions in China. This variation
could be a consequence of different level of health care of
individuals between the two locations studied. The prevalence of
pre-existing Ad5NAb could guide the future administration of Ad5
vector-based products in Beijing and Anhui provinces. However,
our current study has several limitations. Although a fairly large
Different amounts of virus and cell density were used in the neutralization assay (&, 5,000 cells/well; m, 30,000 cells/well), and the percentages of
neutralization were shown for nine serial 3-fold dilutions of Ad5-vaccinated mouse serum, with CLNT (C–E) and FRNT (F–H) assays. Each data point
represents the average of three experiments. (I–J) Ad5NAb titers determination with CLNT (I) and FRNT (J) assays. Each column represents the average
of three experiments. (K–P) FACS analysis of Vero cells infected with Ad5-EGFP expressing the EGFP reporter gene. Incubation with optimized viral
dose (250VP/cell) and cell density (30,000 cells/well) with a 810-fold (M), 2430-fold (N), 7290-fold (O), 21870-fold (P) dilutions of Ad5-vaccinated
mouse serum or without serum (L) resulted in 5.2%, 18.2%, 49.9%, 67.9% or 70.2% EGFP-positive cells, respectively, and uninfected cell control (K)
resulted in 0.4% EGFP-positive cells. The mean percentage of infected cells was shown in each plot. Representative data were shown for three
independent experiments.
doi:10.1371/journal.pone.0037532.g001
Table 1. Description of the final format of the CLNT and FRNT assays.
Step Description
Samples collection Collection by venipuncture. Inactivation of sera at 56uC for 30 min.
Dilution of sera Preparation of seven 3-fold dilution steps in a 96-well plate in volume of 100 ml. Preparation of 150 ml medium for
negative control. A control serum with established Ad5NAb titer was included as a standard.
Addition of virus Dispensing of 50 ml containing 7.5610
6 VP of Ad5-Fluc or Ad5-EGFP to each well. Incubation at 37uC, 5%CO2 for 1 h.
Addition of cells Addition of 100 ml containing 30,000 Vero cells to each well. Incubation at 37uC, 5%CO2 for 24 h.
CLNT measurement Aspiration of 100 ml supernatant. Addition of 100 ml of Bright-Glo
TM luciferin. Incubation at room temperature for
2 min, keeping from light. Measuring luminescence with GLOMAX
TM 96 microplate luminometer.
FRNT measurement The cells were trypsinized, resuspended in DPBS containing 1% FCS, and analyzed by FACS.
doi:10.1371/journal.pone.0037532.t001
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participant sampling was not random and, therefore, may not be
representative of the general population. Taking the high level of
pre-existing Ad5NAb into account, Ad5 vector-based products
should be administered at higher dosage or via the intranasal route
in future studies. Croyle et al [27] showed that nasal immunization
with an Ad5-based vaccine can induce a long-term protective
immune response against Ebola virus in a mouse model which was
not impeded by pre-existing immunity to Ad5. Alternatively,
Osada et al [28] explored a novel strategy that specifically reduced
the expression of structural Ad5 genes by creating E1- and E2b-
deleted recombinant Ad5 vectors to address the pre-existing
Ad5NAb issue.
Comparison of the two current assays used for assessing
Ad5Nab showed that the CLNT was significantly more sensitive
than FRNT, although an excellent correlation and close agree-
ment for the high titer of positive samples between the assays was
found. Consistent with this finding, Yang et al [29] declared that
the sensitivity of the chemiluminescence detection was 10-fold
greater than a fluorescence-based assay, and 80- to 100-fold
greater than a conventional colorimetric method. Maybe, one
reason for the higher sensitivity in CLNT compared to FRNT was
because the trypsinization of Vero cells might lead to increased
lysis of infected cells, especially if they were carrying higher viral
loads. To confirm whether the titers calculated using two assays
were correlated with the actual pre-existing antibodies specifically
recognizing Ad5 proteins, samples with different determined titers
of Ad5NAb were analyzed by western blot. There was 100%
agreement between neutralizing antibody and western blot assays.
Interestingly, difference in the amount of antibody reactive to
three major components of the viral capsid in human sera,
(penton.fiber.hexon) may be determined by the order of
appearance of antibodies during infection. Gahery-Segard et al
[30] previously observed the sequential appearance of these
antibodies with particle-coated enzyme-linked immunosorbent
assay: anti-fiber antibodies appeared first, followed by anti-penton
antibodies, and then by anti-hexon antibodies. However, Bradley
et al [20] observed that neutralizing antibody responses to hexon
appeared be more predominant than anti-fiber antibodies in sera
from vaccinated mice, vaccinated humans, and naturally exposed
humans. Cheng et al [21] demonstrated that rAd5 neutralizing
antibodies were directed to different components of the virion,
Table 2. Ad5NAbs measured by FRNT and CLNT assays.
Variables Num. Num. of cases (%) Sig
a Mean of Ad5NAb (log10)
b
Sig
c
FRNT CLNT FRNT CLNT
Age 18–20 years 48 26 (54.2) 34 (70.8) 0.008 2.2860.85 2.6160.94 ,0.001
21–30 years 49 35 (71.4) 43 (87.8) 0.008 2.4760.80 2.8460.79 ,0.001
31–40 years 55 41 (74.5) 49 (89.1) 0.008 2.5760.90 2.9660.85 ,0.001
41–56 years 54 42 (77.8) 50 (92.6) 0.008 2.4860.78 2.8860.75 ,0.001
Sex Male 99 67 (67.7) 84 (84.8) ,0.001 2.4260.84 2.7860.83 ,0.001
Female 107 77 (72.0) 92 (86.0) ,0.001 2.4960.83 2.8760.85 ,0.001
Site Beijing BC 100 61 (61.0) 79 (79.0) ,0.001 2.3260.77 2.7260.86 ,0.001
Anhui BC 106 83 (78.3) 97 (91.5) ,0.001 2.5960.87 2.9360.81 ,0.001
Total 206 144 (69.9) 176 (85.4) ,0.001 2.4560.84 2.8360.84 ,0.001
FRNT, Fluorescence-based NAb detection test; CLNT, Chemiluminescence-based NAb detection test.
aSignificance calculated using Chi-square test (p-values).
bValues are expressed as mean6SD.
cSignificance calculated using paired t-test (p-values).
doi:10.1371/journal.pone.0037532.t002
Figure 2. Comparison between CLNT and FRNT measurements. (A) Correlation between 50% Ad5 neutralizing antibody titers (log10) of 144
human sera positive by CLNT and FRNT assays. The line represents the fitted regression line. (B) Bland-Altman plot of Ad5NAb measurements using
the CLNT and FRNT assays. Solid line indicates the mean value, and dashed lines represent 95% confidence limits. The x-axis indicates the average of
Ad5NAb titers (log10) of CLNT and FRNT assays. The y-axis indicates the difference between the Ad5NAb titers (log10) of CLNT and FRNT assays.
doi:10.1371/journal.pone.0037532.g002
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vaccination. The vaccine targeted more of the capsid antibody
titer, whereby the natural infection had more specificity to the
fiber. Notably, preexisting immunity to fiber significantly reduced
the CD4 and CD8 cell responses to HIV Gag after rAd5
vaccination. In this study, we found the ratios of penton:fiber
between S52 and S85, which had similar levels of Ad5NAb titers,
were variable . So, it was strongly suggested that both the quantity
and the specificity of Ad5 neutralizing antibodies should be
focused on. Several recombinant Ad5 vectors have been
engineered to circumvent pre-existing anti-Ad5 immunity by
removing key neutralizing epitopes on the surface of viral capsid
proteins, such as Ad5/35 fiber chimeras and Ad5/48 hexon
chimeras [7,23,31]. Such chimeric viral vectors may have
important practical implications for vaccination and gene therapy.
In summary, two simple, objective, reproducible, time- and
labor-saving chemiluminescence-based and fluorescence-based
neutralization assays were developed for the determination of
Ad5NAb titers in human sera. Significantly different levels of
Ad5NAbs were measured in samples by the two assays. Therefore,
due to its sensitivity and simplicity, it is suggested that the CLNT is
the preferred method to be used for future epidemiological studies
of Ad5NAb in other localities.
Methods
Ethics issues
The study design was inspected and approved by Ethical
Committee of Beijing Blood Center. Each participant was
informed of the purpose of the study and written consent was
obtained from each participant involved in this study.
Cells
Vero (ATCC, CCL81) and HEK293 (ATCC, CRL-1573) cells
were used for the CLNT and FRNT neutralizing assay, grown at
37uC under 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 1% L-
glutamine, 1% combined antibiotics and 1% non-essential amino
acids (HyClone, South Logan, UT, USA).
Sera samples
Serum samples from 206 donors (99 males, 107 females)
ranging in age from 18–56 years as of 2011 were obtained from a
diverse human population of healthy individuals in Beijing and
Anhui province, China, with no known prior exposure to Ad5
virus. The samples from healthy participants were collected from
the Beijing BC (100 samples) and Anhui BC (106 samples). There
was roughly a 1:1 male:female in each age group in both Beijing
and Anhui participants. All samples were frozen at 280uC and
banked at the institutions after collection. Samples were shipped
on dry ice to the National Institutes for Food and Drug Control.
All samples were thawed, aliquoted, and stored at 280uC until
assayed. All samples in our study were subjected to identical
treatment and storage conditions, and were considered of
equivalent quality.
Ad5-Fluc and Ad5-EGFP viruses
Using the Fluc and EGFP genes derived from pLUCF and
pDRVI1.0-EGFP, respectively (kindly provided by John T.
Schiller, National Cancer Institute, Bethesda, MD, USA and
Jianqing Xu, Chinese Center for Disease Control and Prevention,
Beijing, China), the Ad5-Fluc and Ad5-EGFP were constructed
according to the AdMax method [32]. Briefly, PCR was used to
construct recombinant shuttle plasmid pDC316-Fluc and
pDC316-EGFP. HEK293 cells were cotransfected with structural
gene expression plasmids (pBHGlox-E1,3Cre) and the reporter
plasmids for Ad5-Fluc and Ad5-EGFP construction using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Recombinant
vectors were serially-passaged on HEK293 cells to generate high-
titer viral stocks.
CLNT and FRNT based Ad5 neutralization assays
Ad5NAb was quantified using the chemiluminescence- assay
and fluorescence-based assays according to established methods in
which the neutralization was measured by the reduction in Fluc
reporter gene expression of recombinant Ad5-Fluc virus and in
percentage of EGFP protein expression positive cells inhibited by
Ad5NAb present in serum samples, respectively. During the
development stages of the assay, the following parameters were
tested: cell density and inoculum dose of virus. Cells density was
tested with 5,000 or 30,000 cells/well in a 96-well flat-bottom
Figure 3. Confirmation of Ad5NAb by western blotting assay. Sample S08 was negative and S79 were positive for Ad5NAb titers for both
assays. Samples S29, S51, S52, S71 and S85 were CLNT-positive/FRNT-negative sera. The uninfected HEK293 cells as negative control was used while
two samples (S71, S29) were performed confirmation by western blotting assay. The Ad5 viral capsid is composed of three major types of proteins:
hexon (130 kDa), penton base (82 kDa), and fiber (62 kDa).
doi:10.1371/journal.pone.0037532.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37532culture plate (Corning-Costar, Tokyo, Japan). In determining the
optimal viral dose for the assay, we considered both the natural
infectivity of the virus in Vero cells and the variability of infection
in the presence of varying dilutions of serum containing Ad5NAb,
involving 63,250, and 1000 VP/cell of diluted viruses and nine
dilutions of anti-Ad5 mouse serum (AAMS), which was collected at
2 weeks after the second Ad5 empty virus inoculation. The diluted
recombinant Ad5 viruses (50 mL) and serial three-fold dilutions of
sera to be tested starting at 1:30 (100 mL) were mixed in each of
three corresponding wells in a 96-well plate, then incubated at
37uC, 5% CO2 for 1 h. Vero cells were added as a trypsinized
single-cell suspension. The assay was incubated for 24 h after
infection. To monitor inter-assay variability, there were at least
two control wells that contained cells plus 150 mL of medium,
acted as blank samples for detection and deduction of the
background.
For the CLNT assay, 100 mL of supernatant was aspirated and
100 mL of D-luciferin substrate (Caliper, Hopkinton, MA, USA)
was added into each well protected from light at room
temperature for 2 min, after which luminescence was measured
using a GLOMAX 96 microplate luminometer (Promega,
Madison, WI). the 50% neutralization titer (NT50) for each serum
sample was defined as the serum dilution at which the relative light
unit (RLU) was reduced by 50% compared with virus-containing
control wells after subtraction of the background RLU in cell-
containing control wells.
For the FRNT assay, the cells were trypsinized, resuspended in
DPBS containing 1% FCS, and analyzed by FACS (BD, Franklin
Lakes, NJ) to evaluate the percentages of positive cells. The NT50
of each serum was defined as the reciprocal of the highest dilution
that reduced the rate of transduced cells by 50% in comparison
with wells containing virus but without antibody. Titers of $30
were accepted positive.
Confirmation of NAb result by western blot analysis
As previously reported, the purified Ad5 viruses (10
10 VP) were
lysed with 1% (v/v) Triton X-100, resuspended in Laemmli lysis
buffer, boiled for 5 min, and subjected to SDS-PAGE and then
transferred to polyvinylidene fluoride membrane (Millipore,
Billerica, MA) [15]. After blocking, the membrane was incubated
for 1 h at room temperature with an equal volume of serum, at a
1:500 dilution, from participants with either negative, low or high
Ad5NAb titers, as determined by CRNT or FRNT. Then, the
membrane was incubated with horseradish peroxidase-conjugated
goat anti-human IgG antibody (Promega, Madison, WI) at a
1:2500 dilution for 1 h. Finally, antibody reactivity was revealed
using the ECL system (GE Healthcare, Piscataway, NJ).
Statistical analysis
The Ad5NAb titer levels in the positive samples measured by
two assays were compared using correlation and Bland-Altman
analyses. Comparisons between the Ad5NAb seroprevalence in
different assays and in different groups were evaluated using the
Chi-square test, and differences in means were assessed using the
Student’s t-test available in SPSS (ver. 18.0; IBM, Armonk, NY). A
p value of ,0.05 was considered significant.
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